Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters











Database
Language
Publication year range
1.
Int J Mol Sci ; 22(23)2021 Nov 24.
Article in English | MEDLINE | ID: mdl-34884503

ABSTRACT

Individual differences in coping with stress may determine either a vulnerable or resilient phenotype. Therefore, it is important to better understand the biology underlying the behavioral phenotype. We assessed whether individual behavioral phenotype to acute stress is related with the hippocampal expression of glucocorticoid receptor (GR), Nurr1, interleukin-1 beta (IL-1ß) or brain-derived neurotrophic factor (BDNF). Wistar male rats were exposed to forced swimming for 15 min and sacrificed at different times. Behavioral response was analyzed, and it was compared with the gene and protein expression of GR, Nurr1, IL-1ß and BDNF in the hippocampus for each time point. Behavioral phenotyping showed a group with high immobility (vulnerable) while another had low immobility (resilient). No significant differences were found in the Nurr1, IL-1ß and BDNF mRNA levels between resilient and vulnerable rats at different recovery times except for Nr3c1 (gene for GR). However, exposure to stress caused significantly higher levels of GR, Nurr1 and IL-1ß proteins of vulnerable compared to resilient rats. This variability of behavioral phenotypes is associated with a differential molecular response to stress that involves GR, Nurr1, and IL-1ß as mediators in coping with stress. This contributes to identifying biomarkers of susceptibility to stress.


Subject(s)
Behavior, Animal/physiology , Brain-Derived Neurotrophic Factor/metabolism , Hippocampus/metabolism , Interleukin-1beta/metabolism , Nuclear Receptor Subfamily 4, Group A, Member 2/metabolism , Receptors, Glucocorticoid/metabolism , Stress, Psychological , Swimming , Adaptation, Psychological , Animals , Brain-Derived Neurotrophic Factor/genetics , Disease Models, Animal , Female , Interleukin-1beta/genetics , Male , Nuclear Receptor Subfamily 4, Group A, Member 2/genetics , Phenotype , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Rats, Wistar , Receptors, Glucocorticoid/genetics
2.
Int J Mol Sci ; 19(12)2018 Nov 27.
Article in English | MEDLINE | ID: mdl-30486451

ABSTRACT

Glioblastoma multiforme is the most malignant and aggressive type of brain tumor, with a mean life expectancy of less than 15 months. This is due in part to the high resistance to apoptosis and moderate resistant to autophagic cell death in glioblastoma cells, and to the poor therapeutic response to conventional therapies. Autophagic cell death represents an alternative mechanism to overcome the resistance of glioblastoma to pro-apoptosis-related therapies. Nevertheless, apoptosis induction plays a major conceptual role in several experimental studies to develop novel therapies against brain tumors. In this review, we outline the different components of the apoptotic and autophagic pathways and explore the mechanisms of resistance to these cell death pathways in glioblastoma cells. Finally, we discuss drugs with clinical and preclinical use that interfere with the mechanisms of survival, proliferation, angiogenesis, migration, invasion, and cell death of malignant cells, favoring the induction of apoptosis and autophagy, or the inhibition of the latter leading to cell death, as well as their therapeutic potential in glioma, and examine new perspectives in this promising research field.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Autophagy/drug effects , Glioblastoma/metabolism , Signal Transduction/drug effects , Animals , Biomarkers , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/metabolism , Clinical Trials as Topic , Drug Discovery , Gene Expression Regulation, Neoplastic , Glioblastoma/drug therapy , Glioblastoma/genetics , Glioblastoma/pathology , Glioma/drug therapy , Glioma/genetics , Glioma/metabolism , Glioma/pathology , Humans , Molecular Targeted Therapy , Treatment Outcome
3.
Stress ; 19(5): 506-15, 2016 09.
Article in English | MEDLINE | ID: mdl-27219004

ABSTRACT

Depending on genetic predisposition, prenatal stress may result in vulnerability or resilience to develop psychiatric disorders in adulthood. Nurr1 is an immediate early gene, important in the brain for the stress response. We tested the hypothesis that prenatal stress and the decrease of hippocampal Nurr1 alter offspring behavioral responses in the forced swimming test (FST). Pregnant Wistar rats were exposed to restraint stress (45 min, thrice daily) from gestation day 14. Prenatally stressed (PS) and non-prenatally stressed (NPS) male offspring were treated bilaterally with a Nurr1 antisense oligodeoxynucleotide (ODN; or control) into the hippocampus at 97 d of age. After 1 h, the rats were exposed to the FST (acute stressor) to analyze their behavioral responses. Thirty minutes after the FST, we analyzed the gene expression of Nurr1, Bdnf and Nr3c1 (genes for Nurr1, brain-derived neurotrophic factor (BDNF) and glucocorticoid receptor (GR), respectively) in the hippocampus, prefrontal cortex (PFC) and hypothalamus. Results showed that the decrease of hippocampal Nurr1 after the antisense ODN in adult NPS rats induces immobility (indicating depressive-like behavior). The PS adult rats, including the group with decreased hippocampal Nurr1, presented low immobility in the FST. This low immobility was concordant with maintenance of Nurr1 and Bdnf expression levels in the three analyzed brain regions; Nr3c1 gene expression was also maintained in the PFC and hypothalamus. These findings suggest that Nurr1 and associated genes could participate in the brain modifications induced by prenatal stress, allowing active coping (resilience) with acute stress in adulthood.


Subject(s)
Adaptation, Psychological/physiology , Nuclear Receptor Subfamily 4, Group A, Member 2/genetics , Prenatal Exposure Delayed Effects/genetics , Stress, Psychological/genetics , Animals , Brain-Derived Neurotrophic Factor/genetics , Brain-Derived Neurotrophic Factor/metabolism , Female , Gene Expression , Hippocampus/metabolism , Hypothalamus/metabolism , Male , Nuclear Receptor Subfamily 4, Group A, Member 2/metabolism , Prefrontal Cortex/metabolism , Pregnancy , Prenatal Exposure Delayed Effects/metabolism , Prenatal Exposure Delayed Effects/psychology , Rats , Rats, Wistar , Receptors, Glucocorticoid/genetics , Receptors, Glucocorticoid/metabolism , Restraint, Physical , Stress, Psychological/metabolism , Stress, Psychological/psychology , Swimming/psychology
4.
Neuropeptides ; 48(4): 221-32, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24819277

ABSTRACT

Molecular chaperones, or heat shock proteins (HSP), have been implicated in numerous neurodegenerative disorders characterized by the accumulation of protein aggregates, such as Alzheimer disease. The agglomeration of insoluble structures of Aß is thought to be responsible for neuronal death, which in turn leads to the loss of cognitive functions. Recent findings have shown that the induction of HSP decreases the level of abnormal protein aggregates, as well as demonstrating that 17-(allylamino)-17-demethoxygeldanamycin (17-AAG), an analogue of geldanamycin (GA), increases Aß clearance through the induction of molecular chaperones in cell culture. In light of this discovery that HSP overexpression can be neuroprotective, the search for a way to pharmacologically induce the overexpression of HSP and other associated chaperones may lead to a promising approach for the treatment of neurodegenerative diseases. The aim of our study was to evaluate both the effect of 17-AAG on the cognitive process and the HSP response in rats injected with Aß25-35 into the CA1 of the hippocampus. The results show that the injection of Aß caused a significant increase in the expression of the HSP involved in the regulation of cellular proteostasis. While the HSP did not reverse excitotoxic damage, given that experimental subjects showed learning and memory deficits, the administration of 17-AAG prior to the injection of Aß25-35 did show an improvement in the behavioral assessment that correlated with the upregulation of HSP70 in subjects injured with Aß. Overall, our data shows that the pharmacological induction of HSP using 17-AAG may be an alternative treatment of neurodegenerative diseases.


Subject(s)
Amyloid beta-Peptides , Benzoquinones/therapeutic use , Cognition Disorders/chemically induced , Cognition Disorders/drug therapy , Cognition/drug effects , Heat-Shock Proteins/biosynthesis , Lactams, Macrocyclic/therapeutic use , Nootropic Agents/therapeutic use , Peptide Fragments , Amyloid beta-Peptides/antagonists & inhibitors , Animals , CA1 Region, Hippocampal/drug effects , CA1 Region, Hippocampal/metabolism , CA1 Region, Hippocampal/pathology , Cognition Disorders/psychology , HSP90 Heat-Shock Proteins/antagonists & inhibitors , Male , Maze Learning/drug effects , Peptide Fragments/antagonists & inhibitors , Rats , Rats, Wistar
5.
Neuropeptides ; 47(5): 339-46, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23850171

ABSTRACT

Two hallmarks of Alzheimer diseases are the continuous inflammatory process, and the brain deposit of Amyloid b (Aß), a cytotoxic protein. The intracellular accumulation of Aß(25-35) fractions, in the absence of Heat Shock proteins (Hsps), could be responsible for its cytotoxic activity. As, pro-inflammatory mediators and nitric oxide control the expression of Hsps, our aim was to investigate the effect of Aß(25-35) on the concentration of IL-1ß, TNF-α and nitrite levels, and their relation to pHSF-1, Hsp-60, -70 and -90 expressions, in the rat C6 astrocyte cells. Interleukin-specific ELISA kits, immunohistochemistry with monoclonal anti-Hsp and anti pHSF-1 antibodies, and histochemistry techniques, were used. Our results showed that Aß25-35 treatment of C6 cells increased, significantly and consistently the concentration of IL-1ß, TNF-α and nitrite 3 days after initiating treatment. The immunoreactivity of C6 cells to Hsp-70 reached its peak after 3 days of treatment followed by an abrupt decrease, as opposed to Hsp-60 and -90 expressions that showed an initial and progressive increase after 3 days of Aß(25-35) treatment. pHSF-1 was identified throughout the experimental period. Nevertheless, progressive and sustained cell death was observed during all the treatment times and it was not caspase-3 dependent. Our results suggest that Hsp-70 temporary expression serves as a trigger to inhibit casapase-3 pathway and allow the expression of Hsp-60 and -90 in C6 astrocytoma cells stimulated with Aß(25-35).


Subject(s)
Amyloid beta-Peptides/metabolism , DNA-Binding Proteins/metabolism , HSP70 Heat-Shock Proteins/metabolism , Peptide Fragments/metabolism , Transcription Factors/metabolism , Amyloid beta-Peptides/pharmacology , Animals , Astrocytoma , Cell Death , Cytokines/analysis , Cytokines/metabolism , Heat Shock Transcription Factors , Inflammation/metabolism , Nitric Oxide/analysis , Nitric Oxide/metabolism , Peptide Fragments/pharmacology , Phosphorylation , Rats , Tumor Cells, Cultured
6.
Neuropathology ; 31(2): 162-9, 2011 Apr.
Article in English | MEDLINE | ID: mdl-20667006

ABSTRACT

Prion diseases are caused by an abnormal form of the prion protein (PrP(Sc)). We identified, with lectins, post-translational modifications of brain proteins due to glycosylation in a Gerstmann-Sträussler-Scheinker (GSS) patient. The lectin Amaranthus leucocarpus (ALL), specific for mucin type O-glycosylated structures (Galß1,3 GalNAcα1,0 Ser/Thr or GalNAcα1,0 Ser/Thr), and Sambucus nigra agglutinin (SNA), specific for Neu5Acα2,6 Gal/GalNAc, showed positive labeling in all the prion deposits and in the core of the PrP(Sc) deposits, respectively, indicating specific distribution of O-glycosylated and sialylated structures. Lectins from Maackia amurensis (MAA, Neu5Acα2,3), Macrobrachium rosenbergii (MrL, Neu5,9Ac2-specific) and Arachis hypogaea (PNA, Gal-specific) showed low staining of prion deposits. Immunohistochemistry colocalization with prion antibody indicated that all lectins stained prion protein deposits. These results show that specific modifications in the glycosylation pattern are closely related to the hallmark lesions and might be an early event in neuronal degeneration in GSS disease.


Subject(s)
Gerstmann-Straussler-Scheinker Disease/metabolism , Polysaccharides/metabolism , PrPSc Proteins/metabolism , Gerstmann-Straussler-Scheinker Disease/pathology , Humans , Immunohistochemistry , Lectins , Microscopy, Confocal , Microscopy, Electron, Transmission , Middle Aged , Protein Processing, Post-Translational
7.
Synapse ; 65(6): 497-504, 2011 Jun.
Article in English | MEDLINE | ID: mdl-20936686

ABSTRACT

In our study we investigated the influence of dopamine (DA) on the caudal photoreceptor (CPR) in crayfish. Here we report the following: (a) the chromatographic determination of DA in the sixth abdominal ganglion (6th AG) shows a variation in the content during a 24-h cycle with the maximum value at dawn. (b) There are possibly dopaminergic neurons in the 6th AG with antityrosine hydroxylase antibodies. Immunopositive neurons (164) were located in the anterior and posterior regions of the 6th AG with the mean (± SE) diameter of their somata 23 ± 1 µm. In addition, there is immunopositive staining in axons, neuropilar fibers, and varicosities. (c) We also identified, using immunohistochemistry, 108 neurons in the sixth AG that contain dopamine D1-like receptors, with the mean (±SE) diameter of their somata 18 ± 1 µm. (d) We examined the exogenous action of DA on the electrical activity of the CPR in the isolated sixth AG by conventional extracellular-recording methods. This CPR displays spontaneous activity and phasic-tonic responses to light pulses. Topical application of dopamine to ganglia kept in the dark increased the spontaneous firing rate of the CPR, whereas the photoresponse of the CPR remained unchanged. The effect on the spontaneous activity is dose-dependent with an ED50 of 33 µM, and is blocked by the dopamine D1-like antagonist SCH23390. These observations suggested that the DA is playing the role of a neurotransmitter or a neuromodulator of the CPR in the 6th AG in both species of crayfish, Procambarus clarkii and Cherax quadricarinatus.


Subject(s)
Dopamine/physiology , Ganglia, Invertebrate/metabolism , Photoreceptor Cells, Invertebrate/metabolism , Animals , Astacoidea , Circadian Rhythm/physiology , Female , Ganglia, Invertebrate/cytology , Ganglia, Invertebrate/enzymology , Male , Photoreceptor Cells, Invertebrate/drug effects , Photoreceptor Cells, Invertebrate/radiation effects , Presynaptic Terminals/enzymology , Presynaptic Terminals/metabolism , Presynaptic Terminals/ultrastructure , Tyrosine 3-Monooxygenase/metabolism
8.
Neurosci Lett ; 468(2): 151-5, 2010 Jan 04.
Article in English | MEDLINE | ID: mdl-19879921

ABSTRACT

Alzheimer's disease (AD) is characterized by the amyloid-beta (Abeta) aggregation but it is unclear when this process begins. Previously, we showed that amyloid-beta(25-35) (Abeta(25-35)) increases the nitric oxide (NO) pathways and causes neurodegenerative effects in rats. The excessive increase of NO during brain development can promote a persistent oxidative stress, but the role of the Abeta(25-35) in the neonatal age and its effects over the long term is unclear. Our aim was to evaluate if the Abeta(25-35) injection on postnatal day 7 causes loss in spatial memory by NO pathways in adult rats. Our results showed that neonatal-Abeta(25-35) injection into the hippocampus (Hp) causes significant impairments in the spatial memory after 90 days. The NO levels were found increased and argynophilic in the Hp. Other evidence of neuronal damage was an increase of the immunoreactivity for 3-nitrotyrosine (3-NT) and the glial-fibrilar acid protein (GFAP) in the Hp of the Abeta(25-35) group. In contrast, these effects were blocked by the administration of L-NAME (inhibitor of nitric oxide synthase) before the injection of Abeta(25-35). The L-NAME plus Abeta(25-35) group showed a better performance in the spatial memory compared to the Abeta(25-35) group. In addition in this group we found a decrease of NO, 3-NT and neurodegeneration in the Hp compared to the Abeta(25-35) group. This finding is a novel result about the role of Abeta(25-35) during the neonatal stage that enhances the NO production, which appears to impair the spatial memory in adult rats.


Subject(s)
Amyloid beta-Peptides/metabolism , CA1 Region, Hippocampal/metabolism , Nitric Oxide/metabolism , Peptide Fragments/metabolism , Amyloid beta-Peptides/toxicity , Animals , Animals, Newborn , CA1 Region, Hippocampal/pathology , Glial Fibrillary Acidic Protein/metabolism , Immunohistochemistry , Injections, Intraventricular , Maze Learning , Memory , NG-Nitroarginine Methyl Ester/pharmacology , Nitric Oxide Synthase/antagonists & inhibitors , Peptide Fragments/toxicity , Rats , Rats, Wistar , Spatial Behavior , Tyrosine/analogs & derivatives , Tyrosine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL